TC-1827 is an
orally active, selective
agonist of the
α4β2 nicotinic receptors. Administration of TC-1827 improved memory and learning in a variety of rodents and increased
long-term potentiation in
hippocampal slices. In addition, the compound was without significant cardiovascular side effects, except for a small, transient rise in
arterial blood pressure. The pro-cognitive effects of TC-1827 last much longer than the short half life (0.2 - 1.0 hours) would suggest.[1]
References
^Bohme, Georg Andrees (May 2004). "In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity". Drug Development Research. 62 (1): 26–40.
doi:
10.1002/ddr.10352.
S2CID86072368.